Ultrasound technology developer Misonix announced promising results for the firm's Sonablate 500 high-intensity focused ultrasound (HIFU) clinical trial in the U.K. for hemiablation procedures for prostate cancer treatment.
Tthe results show that the hemiablation procedures were successfully completed with positive ablation of cancerous tissue in the effected area of the prostate gland, and patients showed 100% continence and 100% potency in follow-up examinations, according to the Farmingdale, NY-based firm.
The study is being conducted at the University College London Hospitals NHS Trust (UCLH) to evaluate hemiablation therapy using HIFU in the treatment of localized adenocarcinoma of the prostate, Misonix said.
By AuntMinnie.com staff writers
March 29, 2007
Related Reading
Misonix establishes HIFU clinical registry, March 27, 2007
Misonix reports HIFU kidney trial success, March 22, 2007
Misonix, Partnermed sign Scandinavian HIFU deal, March 6, 2007
Constantine leaves Misonix, January 9, 2007
Misonix gets new credit facility, January 4, 2007
Copyright © 2007 AuntMinnie.com
